A new theranostic drug targets different cancer types.

Published Date: 28 Jun 2023

In preclinical models, a recently identified radionuclide-based agent (CB-2PA-NT) has been demonstrated to have high tumor uptake, sustained tumor retention, and high contrast, making it an excellent candidate for a novel theranostics strategy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer

2.

New CAR T-Cell Therapy Approved for Leukemia

3.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment

4.

Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care

5.

Guideline on management of early-stage non-small cell lung cancer released


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot